However, the survival of patients with increased expression of BTAK or E2F1 is significantly lower than that of patients without this alteration, which suggests that overexpression of these genes probably increases the number of malignant ESCC phenotypes and may be a useful marker of poor prognosis (Fujita et al., 2003). This evidence concerns the gene AURKA and esophageal squamous cell carcinoma.